Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its intention to conduct an underwritten public offering of common stock. The offering is dependent on market conditions, with no certainty regarding its completion or specific terms. EyePoint plans to utilize the net proceeds for advancing EYP-1901, pipeline initiatives, and general corporate purposes. Underwriters Cowen and Guggenheim Securities will lead the offering, which is registered under Form S-3 with the SEC. A preliminary prospectus will provide additional details as it becomes available.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated a Phase 1 clinical trial for EYP-1901, an innovative twice-yearly sustained delivery treatment targeting wet age-related macular degeneration (wet AMD). The trial will involve thirteen patients previously responsive to anti-VEGF treatments, focusing on safety and visual acuity outcomes. EYP-1901 utilizes the proprietary Durasert® technology combined with vorolanib, which previously showed efficacy in Phase 2 trials. This advancement could enhance treatment convenience and market potential, particularly for millions affected by wet AMD.

EyePoint Pharmaceuticals (EYPT) provided a business update for Q4 and full-year 2020, showing estimated net product revenues ranging from $6.2M to $6.6M, down from $7.9M in 2019. EYP-1901, a potential anti-VEGF treatment for wet AMD, had an IND filed in December 2020, with a Phase 1 trial expected in Q1 2021. Customer demand for DEXYCU and YUTIQ rose by 30% and 10%, respectively. Cash and cash equivalents were approximately $44M as of December 31, 2020. A partnership with Ocumension Therapeutics brought a $15.7M injection, and a royalty agreement with SWK Holdings added $16.5M.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a $15.7 million equity investment from Ocumension Therapeutics, a Chinese ophthalmic company. Ocumension acquired approximately 3.01 million shares at a price of $5.22 per share as of December 29, 2020. The investment marks a significant partnership for the commercialization of EyePoint's products, YUTIQ and DEXYCU, in Asia. The company estimates cash and cash equivalents at around $44 million as of December 31, 2020, which will support operations into the latter part of 2021, assuming no major disruptions due to COVID-19.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has entered a royalty monetization agreement with SWK Holdings for royalties related to its ILUVIEN® product. The deal provides EyePoint with a one-time payment of $16.5 million, of which $15 million will reduce long-term debt and $1.5 million will support product development. This transaction is expected to lower annual interest payments by approximately $1.7 million, enhancing EyePoint's financial stability as it advances its ocular disease pipeline, including EYP-1901 for wet age-related macular degeneration.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a 1-for-10 reverse stock split effective at 5:00 p.m. ET on December 8, 2020. Starting December 9, 2020, the stock will trade under a new CUSIP number. The move aims to regain compliance with Nasdaq's $1.00 minimum closing bid price requirement. The split reduces the number of outstanding shares from approximately 151.3 million to about 15.13 million, affecting all stockholders uniformly. The company's authorized shares and par values remain unchanged. Computershare is appointed as the exchange agent for this process.

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported positive results from its preclinical toxicology study of EYP-1901, a six-month sustained delivery treatment for wet age-related macular degeneration (AMD). No adverse findings related to EYP-1901 were observed, and key ocular measurements remained stable. The company plans to file for Investigational New Drug (IND) status by the end of 2020 and initiate a Phase 1 clinical trial in early 2021. EYP-1901 aims to offer a long-term treatment option for wet AMD, with potential future applications in diabetic retinopathy.

On November 19, 2020, EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a virtual roundtable discussion on December 4, 2020, at 12:00 p.m. ET, focusing on local drug delivery for wet age-related macular degeneration (AMD) and EYP-1901, a potential six-month sustained delivery therapy. Esteemed retina specialists, including Robert Avery, M.D., and Elias Reichel, M.D., will participate. Interested parties can access the event by phone or via a live webcast on the company's website.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced positive data for its ophthalmic products YUTIQ and DEXYCU during the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. The second Phase 3 trial for YUTIQ showed a significantly lower recurrence rate of uveitis (46.5% vs. 75%). A multicenter study confirmed DEXYCU's effectiveness in reducing inflammation after cataract surgery, while a comparison study indicated DEXYCU's superiority over traditional eye drops in pain control and patient preference. These findings support the long-term advantages of both products.